In vitro activity of telavancin against a contemporary worldwide collection of staphylococcus aureus isolates

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 6, 2010, Pages 2704-2706

  Mendes, Rodrigo E ^a   Moet, Gary J ^a   Janechek, Mike J ^a   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; TEICOPLANIN; TELAVANCIN; VANCOMYCIN;

ARTICLE; BACTERIUM ISOLATE; DRUG ACTIVITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ACETAMIDES; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; HUMANS; METHICILLIN RESISTANCE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; VIRGINIAMYCIN;

EID: 77952603485     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00301-10     Document Type: Article

References (19)

1. Astellas Pharma Global Development, Inc. Last accessed 8 January 2010. VIBATIV package insert. Astellas Pharma Global Development, Inc., Deerfield, IL. http://www.vibativ.com.
2. Clinical and Laboratory Standards Institute. 2006. M07-A7, Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-seventh edition. Clinical and Laboratory Standards Institute, Wayne, PA.
3. Clinical and Laboratory Standards Institute. 2009. M100-S19. Performance standards for antimicrobial susceptibility testing. 19th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Cornaglia, G., and G. M. Rossolini. 2009. Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens. Clin. Microbiol. Infect. 15:218-223.
5. Cosgrove, S. E., and V. G. Fowler, Jr. 2008. Management of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46(Suppl. 5): S386-S393.
6. Draghi, D. C., B. M. Benton, K. M. Krause, C. Thornsberry, C. Pillar, and D. F. Sahm. 2008. Comparative surveillance study of telavancin activity against recently collected Gram-positive clinical isolates from across the United States. Antimicrob. Agents Chemother. 52:2383-2388.
7. Draghi, D. C., B. M. Benton, K. M. Krause, C. Thornsberry, C. Pillar, and D. F. Sahm. 2008. In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. J. Antimicrob. Chemother. 62:116-121.
8. Dunbar, L. M., D. M. Tang, and R. M. Manausa. 2008. A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI). Ther. Clin. Risk Manag. 4:235-244.
9. Hayden, M. K., K. Rezai, R. A. Hayes, K. Lolans, J. P. Quinn, and R. A. Weinstein. 2005. Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J. Clin. Microbiol. 43:5285-5287.
10. Hidron, A. I., J. R. Edwards, J. Patel, T. C. Horan, D. M. Sievert, D. A. Pollock, and S. K. Fridkin. 2008. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect. Control Hosp. Epidemiol. 29:996-1011.
11. Higgins, D. L., R. Chang, D. V. Debabov, J. Leung, T. Wu, K. M. Krause, E. Sandvik, J. M. Hubbard, K. Kaniga, D. E. Schmidt, Jr., Q. Gao, R. T. Cass, D. E. Karr, B. M. Benton, and P. P. Humphrey. 2005. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49:1127-1134.
12. Jansen, W. T., A. Verel, J. Verhoef, and D. Milatovic. 2007. In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe. Antimicrob. Agents Chemother. 51:3420-3424.
13. Jones, R. N. 2008. Key considerations in the treatment of complicated staphylococcal infections. Clin. Microbiol. Infect. 14(Suppl. 2):3-9.
14. Krause, K. M., M. Renelli, S. Difuntorum, T. X. Wu, D. V. Debabov, and B. M. Benton. 2008. In vitro activity of telavancin against resistant grampositive bacteria. Antimicrob. Agents Chemother. 52:2647-2652.
15. Leuthner, K. D., C. M. Cheung, and M. J. Rybak. 2006. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 58:338-343.
16. Lunde, C. S., S. R. Hartouni, J. W. Janc, M. Mammen, P. P. Humphrey, and B. M. Benton. 2009. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob. Agents Chemother. 53:3375-3383.
17. Neoh, H. M., S. Hori, M. Komatsu, T. Oguri, F. Takeuchi, L. Cui, and K. Hiramatsu. 2007. Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections. Ann. Clin. Microbiol. Antimicrob. 6:13.
18. Sakoulas, G., P. A. Moise-Broder, J. Schentag, A. Forrest, R. C. Moellering, Jr., and G. M. Eliopoulos. 2004. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42:2398-2402.
19. Stryjewski, M. E., D. R. Graham, S. E. Wilson, W. O'Riordan, D. Young, A. Lentnek, D. P. Ross, V. G. Fowler, A. Hopkins, H. D. Friedland, S. L. Barriere, M. M. Kitt, and G. R. Corey. 2008. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms. Clin. Infect. Dis. 46:1683-1693.